Adial Pharmaceuticals (ADIL) Stock Statistics & Valuation Metrics

Adial Pharmaceuticals has a market cap or net worth of $2.80M. The enterprise value is -$4.00M.

Adial Pharmaceuticals has 1,427,970 shares outstanding. The number of shares has decreased by -2.65% in one year.

Adial Pharmaceuticals’s return on equity (ROE) is -1.51 and return on invested capital (ROIC) is -147.82%.

The current PE Ratio of Adial Pharmaceuticals is ―. Adial Pharmaceuticals’s PEG ratio is 0.01.

In the last 12 months, Adial Pharmaceuticals had revenue of 0.00 and earned -7.98M in profits. Earnings per share was -11.93.

In the last 12 months, operating cash flow was -6.49M and capital expenditures -1.00, giving a free cash flow of -6.49M billion.

Adial Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Adial Pharmaceuticals upcoming earnings date is May 20, 2026, Before Open (Confirmed).

Adial Pharmaceuticals as a current ratio of 4.42, with Debt / Equity ratio of 0.00%

In the past 12 months, Adial Pharmaceuticals has paid 0.00 in taxes.

Adial Pharmaceuticals EV to EBITDA ratio is 0.28, with an EV/FCF ratio of 0.34.

Adial Pharmaceuticals has $5.88M in cash and marketable securities with $0.00 in debt, giving a net cash position of $5.88M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Adial Pharmaceuticals is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy